RGD Reference Report - Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study.

Authors: Machold, KP  Neumann, K  Smolen, JS 
Citation: Machold KP, etal., Ann Rheum Dis. 1992 Sep;51(9):1039-43.
RGD ID: 8157623
Pubmed: PMID:1417133   (View Abstract at PubMed)
PMCID: PMC1004833   (View Article at PubMed Central)

Interferon gamma (IFN gamma) has been advocated in open studies as a beneficial remission inducing drug for the treatment of rheumatoid arthritis (RA). The work reported here was designed to assess the therapeutic potential of IFN gamma in the treatment of RA in a double blind placebo controlled study. It was found that patients treated with IFN gamma improved significantly with respect to morning stiffness, grip strength, swelling of an index joint, and erythrocyte sedimentation rate. Furthermore significantly more responders (according to predetermined response criteria) were found in the group treated with IFN gamma. Only minor adverse effects and no significant toxicity with respect to clinical or laboratory parameters were observed.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
rheumatoid arthritis treatmentIDA 8157623 RGD 
rheumatoid arthritis treatmentISOIFNG (Homo sapiens)8157623; 8157623 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ifng  (interferon gamma)

Genes (Mus musculus)
Ifng  (interferon gamma)

Genes (Homo sapiens)
IFNG  (interferon gamma)


Additional Information